Provexis Share Discussion Threads

[buywell3] 02/8/2019 07:24

Your bias though are you not

Having held these from 7p and down to 0.3p

[gunsofmarscapone] 02/8/2019 07:24

Hope so mate, need 0.41 on the bid to break even. Marked up this morning I notice, tends to suck people in for some reason.

[redprince] 02/8/2019 07:21

The funds needed to stay afloat should be relatively modest imho given that we are not
incurring any further r&d costs.Our main expenses are bod remuneration and patent filing costs.
Provexis has a huge global patent protection portfolio which at some point will make this company very valuable.

Aimho.Dyor.

[gunsofmarscapone] 02/8/2019 07:19

Yes you are right, very secretive about deal metrics. Uninvestable really but yes, worth a punt. They seem to have a clutch of investopunters, stuck in here for double digit years!

[rumobejo] 02/8/2019 07:11

and they also said they need to raise funds in the results rns hence the rampy rns today, suckers alert!!!!

[gunsofmarscapone] 02/8/2019 07:00

So..delighted...open ended...all costs covered etc....transformative even. The Q is, how much of the Mcap is I.P versus fwd P/E etc. Fwiw I’ve had Pxs down as a potential £100 Mil company based on Fruitflow and it’s proven efficacy re thrombus avoidance and more latterly blood pressure control.

Is my tomato capsule based puntvestment going to pay off? Bloody hope so. In the meantime daily dosing of fruitflow with omega3 reduced systolic blood pressure by just under 10mm Hg.

Cannot actually believe everyone doesnt take it, one of the very few compounds in the health food market which is proven to work!!

[senor_sensible] 02/8/2019 06:59

with a bit of momentum this could more than double very quickly, this is the news this stock has been waiting for.......

[senor_sensible] 02/8/2019 06:39

more like it:
2 August 2019



Provexis plc



("Provexis" or the "Company")



Collaboration agreement with By-Health Co., Ltd.





Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is delighted to confirm it has entered into a collaboration agreement (the 'Agreement') with By-Health Co., Ltd. ('By-Health'), a £3bn listed Chinese dietary supplement business, to support the planned launch of some Fruitflow based products in the Chinese market.



The Agreement has been structured on an open-ended framework basis, enabling the parties to conduct a number of different projects over an unspecified period of time under the one overriding agreement, with all projects envisaged to be at By-Health's sole expense.



It is envisaged that projects conducted under the agreement will be focussed on specific areas of commercial focus for By-Health, and the first project which has been agreed will concentrate on the use of Fruitflow with nitrates in exercise, an area of considerable commercial interest to By-Health in China.



It is envisaged that project work will be managed and conducted by Provexis primarily in the UK, led by Provexis' Chief Scientific Officer Dr Niamh O'Kennedy and supported by outsourced research partners which will be appointed and managed by Provexis.



The Fruitflow with nitrates in exercise project will provide gross income to Provexis in excess of £55k, to include an element of overhead recovery. The project will not affect the ownership of Provexis' existing, substantial intellectual property for the Fruitflow with nitrates formulation, which already has patents granted in the UK and Australia. Further patents for this formulation are being sought in Europe, the US, China and eleven other territories, with potential patent protection out to December 2033. All other commercial terms of the Agreement remain confidential between the two parties.



The Company has previously announced it was working with DSM and By-Health to support the planned launch of some Fruitflow based products in the Chinese market, and in a Trading Update on 31 July 2019 the Company confirmed that:



· Provexis and By-Health had been working on a proposed new framework research collaboration agreement for Fruitflow, planned to be at By-Health's sole expense.



· The planned launch by By-Health of a number of Fruitflow based products in the Chinese market, with potential volumes at a significant multiple of existing Fruitflow sales, is progressing well, with activities driven at present by the need to obtain 'blue cap' health claim status for Fruitflow as a dietary supplement with the Chinese State Administration for Market Regulation (SAMR).



· Clinical studies conducted in China are typically required to obtain blue cap health claim status, and a significant investment in seven separate studies, in support of the Fruitflow based products which By-Health plans to launch in China, is being undertaken at By-Health's expense.



· Three studies have been successfully completed in China, three studies are currently ongoing at Chinese clinical sites and a further planned human study in 2019 has been confirmed by By-Health.



· The three completed studies (a human study and two animal studies) showed excellent results in use for Fruitflow, and they provide strong evidence for By-Health in its blue cap and other regulatory submissions to the SAMR for Fruitflow, supported by the Company's existing European Food Safety Authority ('EFSA') health claim for Fruitflow.



· If a successful blue cap health claim is achieved for Fruitflow it would currently be expected to result in some significant orders for Fruitflow, potentially at a multiple of current total sales values.



The Company's Trading Update on 31 July 2019 stated that completion of a collaboration agreement with By-Health was at that time uncertain, an uncertainty which has been removed by way of this announcement of 2 August 2019.



Ian Ford, CFO and COO of Provexis, commented:

'We are delighted to announce this open-ended collaboration agreement with By-Health, which further strengthens the already close relationship between By-Health and Provexis.



By-Health has already made a substantial investment at its sole expense in the clinical trials which it has been conducting in China, seeking to secure blue cap health claim status for Fruitflow. The Company is very pleased to be able to assist By-Health with its commercialisation plans for Fruitflow in China, by way of this new investment with Provexis in the UK, and it will seek to undertake further projects for By-Health under this flexible framework agreement.



The clinical studies which By-Health has been conducting in China have been progressing well and the completed studies have shown excellent results in use for Fruitflow, providing strong evidence for By-Health in its blue cap and other regulatory submissions to the Chinese SAMR.



If a successful blue cap health claim is achieved for Fruitflow in China it would currently be expected to result in some significant orders for Fruitflow, potentially at a multiple of current total sales values. The Company will provide shareholders with as much information as it can with regard to the timing of this commercially sensitive and potentially transformative process.'



Felix Zhang, MSc PhD, Group Director Science & Technology Centre, and Director, Nutrition & Health Research Centre of By-Health Co., Ltd., commented:

'We are delighted to have entered into this open-ended collaboration with Provexis, and look forward to progressing our work with Fruitflow, in partnership with Provexis, towards future significant commercialisation in China.'

[redprince] 31/7/2019 09:42

Glad to see that expenses on the r&d front are being held down as i was concerned by the potential for the funding of the MOU to dilute us further.

Winner i would urge some caution as to the potential wait - 3 more tests to go yet and the last one was 5 months late.

Aimho.Dyor.

[redprince] 31/7/2019 09:42

Glad to see that expenses on the r&d front are being held down as i was concerned by the potential for the funding of the MOU to dilute us further.

Winner i would urge some caution as to the potential wait - 3 more tests to go yet and the last one was 5 months late.

Aimho.Dyor.

[winner31] 31/7/2019 07:26

I am topping up! as I can only see upside from here , news in the next few months will be transformative .

[buywell3] 31/7/2019 07:17

0.2p is now a buywell call on PXS

dyor

[senor_sensible] 31/7/2019 07:14

Would have liked to see profit starting from By-health by now, the significant business in China is still around the corner. hold and add IMO, Might see a small market adjustment upwards.....

[winner31] 31/7/2019 07:04

Only limited fund raise so not bothered by that , you need to focus on the ‘transformative ‘ statement which will take the company into profit .

[buywell3] 31/7/2019 06:11

Another cash raise IMMINENT


'' while the Company remains in a loss-making position it will need to raise funds to support working capital on occasions. The Company is expected to report cash at bank of £326k at its 31 March 2019 year end, and based on its current level of cash it will be seeking to raise further limited funds in the coming months.''

[buywell3] 31/7/2019 06:09

Results as expected IMO


''Underlying operating loss for the year was £385k (2018: £362k), reflecting a £48k year on year increase ''

[wheelds] 30/7/2019 22:22

DSM is our partner, so could By-Health by us out without DSM agreeing.????

[bareknee] 30/7/2019 20:05

I'm not sure anyone can be proved right or wrong unless they say beforehand what they're thinking ! Except to themselves obviously, but that's pretty meaningless.

[redprince] 30/7/2019 09:33

My take fwiw and in part i hope to be proven wrong:

~Waiting for SAMR application results and hoping this provides enough momentum (with some more carrot dangling) to allow more dilution for the purpose of funding the MOU.

I genuinely oppose any more fund raising for research.Any more r&d needs to happen only when it can be paid for organically.


We should know by tomorrow.

Not sure what you are on about winner?

[wheelds] 29/7/2019 17:01

Winner31:- your right.

[winner31] 28/7/2019 21:14

It’s just dawned on me what’s going on here ,after looking at all the rns’s over the last few months I think it’s pretty obvious,well in my mind anyway , i’m not going to explain my thinking but will be proved right or wrong this week .

[winner31] 09/7/2019 20:11

Bareknee agree they have not done themselves any favours with the sequence of events, in fairness things have not been in their control and have probably been waiting for by health to get things done . The trouble is if financially things have improved they have got to tell the market , you will note that there wasn’t an update last year and of course the reason for that was that income was flat £228k in 17 £236k 2018 ,so that is why I believe they are giving an update ,but of course if they give an update on income they would have to say what is happening in China and I don’t think that is quite ready for release yet , just my opinion of course

[bareknee] 09/7/2019 19:42

Winner

Re

"let’s put this straight the April rns of a trading update told me that they were awaiting some news , in the past trading or pre close updates have come on the last day of that years-trading ,so it is possible to announce figures that are pretty well spot on within days of End-of year"

Nah, that's rubbish. The last trading update they issued bang on end of year was back in 2014. There wasn't one last year and the trading updates in 2017 and 2016 were issued mid May and end of June respectively, so what you said wasn't exactly accurate


Re "it is obvious they were in discussions ( as they told us ) with By health but it has taken a bit longer to cross the Ts and dot the i’s and-when that is complete they will issue a statement"

Yea, agree with you on this. They've previously said they were expecting to get the agreement tied up in H1 2019, but that plainly hasn't happened yet. They have though, shot themselves in the foot by then, when announcing O'Kennedy as a director, scheduling an update in June which they then delayed. When the agreement's signed and they announce it, then all will be forgiven, but, until then, as far as I'm concerned, they look like numpties.

BB